Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Podcast: Progress in PARP inhibitors - An exciting option for treating metastatic prostate cancer?
dec 2023 | Uro-oncologie